Sugi Predict

Sugi Predict / Compounds / SCHEMBL319890

SCHEMBL319890

SCHEMBL319890

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3OC1CC(NO)C(O)C(C)O1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S100A4 P26447 6/20 0.84
▸ MEN1 O00255 9/20 0.82
▸ THRB P10828 9/20 0.82
▸ KMT2A Q03164 9/20 0.82
▸ BLM P54132 8/20 0.82
▸ RECQL P46063 7/20 0.82
▸ BRCA1 P38398 6/20 0.82
▸ SMN1; SMN2 Q16637 6/20 0.82
▸ HIF1A Q16665 6/20 0.82
▸ MAPT P10636 6/20 0.82
▸ TDP1 Q9NUW8 6/20 0.82
▸ CYP3A4 P08684 4/20 0.82
▸ USP2 O75604 4/20 0.82
▸ MAPK1 P28482 4/20 0.82
▸ TOP2A P11388 4/20 0.82
▸ HTT P42858 4/20 0.82
▸ CYP1A2 P05177 3/20 0.82
▸ CHRM1 P11229 3/20 0.82
▸ TBXA2R P21731 3/20 0.82
▸ KDM4E B2RXH2 3/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5859468 0.99 S100A4 (0.83) S100A4MEN1THRBKMT2ABLM
SCHEMBL248564 0.95 S100A4 (0.85) S100A4MEN1THRBKMT2ABLM
SCHEMBL14164316 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
SCHEMBL10968257 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
SCHEMBL27825155 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
SCHEMBL3763974 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
Hydrochloric Acid SCHEMBL331063 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
SCHEMBL13943294 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
SCHEMBL11563422 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM
Hydrochloric Acid SCHEMBL28160744 0.94 S100A4 (0.84) S100A4MEN1THRBKMT2ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4611903-A1 METHODS OF TREATING NON-HODGKIN LYMPHOMA TeneoTwo, Inc. (US) 2025-09-10 — — EP claimed
US-20250011418-A1 CANCER SPECIFIC PLECTIN-1 SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF ZIELBIO, INC. 2025-01-09 — — US claimed
EP-4427810-A2 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY Juno Therapeutics, Inc. (US) 2024-09-11 — — EP claimed
CN-118524843-A Treatment of B cell malignancies 阿迪塞特治疗公司 2024-08-20 — — CN claimed
WO-2024097218-A1 METHODS OF TREATING NON-HODGKIN LYMPHOMA TeneoTwo, Inc. (US) 2024-05-10 — — WO claimed
EP-3886875-B1 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY JUNO THERAPEUTICS INC (US) 2024-05-08 — — EP claimed
CN-116322769-A Methods for treating multiple myeloma 詹森生物科技公司 2023-06-23 — — CN claimed
WO-2022232420-A1 CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CANCER INSMED INCORPORATED (US) 2022-11-03 — — WO claimed
US-20220088070-A1 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY JUNO THERAPEUTICS, INC. (US) 2022-03-24 — — US claimed
EP-3886875-A2 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY Juno Therapeutics, Inc. (US) 2021-10-06 — — EP claimed
CN-101772500-A Imidazopyrazines as protein kinase inhibitors SCHERING CORP 2010-07-07 — — CN claimed
CN-101341166-A Synthesis of epirubicin from 13-dihydrodaunorubicine SOLUX CORP (US) 2009-01-07 — — CN claimed
EP-1963348-A4 SYNTHESIS OF EPIRUBICIN FROM 13-DIHYDRODAUNORUBICINE SOLUX CORP (US) 2008-12-10 — — EP claimed
CN-101262876-A Method of treating B cell malignancies with TACI-IG fusion molecules ZYMOGENETICS INC (US) 2008-09-10 — — CN claimed
EP-1963348-A2 SYNTHESIS OF EPIRUBICIN FROM 13-DIHYDRODAUNORUBICINE Solux Corporation (US) 2008-09-03 — — EP claimed
WO-2007076345-A2 SYNTHESIS OF EPIRUBICIN FROM 13-DIHYDRODAUNORUBICINE SOLUX CORPORATION (US) 2007-07-05 — — WO claimed
US-20070142309-A1 SYNTHESIS OF EPIRUBICIN FROM 13-DIHYDRODAUNORUBICINE SYNBIAS PHARMA LTD (UA) 2007-06-21 — — US claimed
CN-1375332-A Composition and method for making Akt cancer gene inactivate and activating P38 precell fade-out gene UNIV TEXAS (US) 2002-10-23 — — CN claimed
CN-85107562-B Method for improving solubility of anthracycline glycoside compound in injection solution 法米塔利亚·卡洛·埃巴公司 1988-06-01 — — CN claimed
CN-85107562-A Contain anthracene nucleus glucosides preparation of drug combination method — 1986-07-23 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142309-A1 SYNTHESIS OF EPIRUBICIN FROM 13-DIHYDRODAUNORUBICINE DUT, HDAC11, NAA15 S100A4 3770/4885MEN1 4251/4885THRB 3077/4885
US-20220088070-A1 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY BCL6, BCL3, CD22 S100A4 1860/4885MEN1 2811/4885THRB 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.